An interventional study of P200TxE and P200DTx in Retinal Disease, sponsored by Optos, PLC. Completed at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Optos, PLC · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 162 studies in Retinal Diseases with a site in United States — 25 open to participants now, 41 under way, 5 of them phase 3. Retinal Diseases · United States.
Among the 162 studies in Retinal Diseases with a site in United States, this one is the 53rd largest by enrollment of the 111 interventional ones that give a count, is one of 16 that started in 2019, is one of 27 with no phase, and was the 89th registered.
333 studies on the registry are indexed under Retinal Diseases; 59 are open to participants now.
Browse Retinal Diseases studies →25 of the 162 studies in Retinal Diseases with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 0 days–9 mo
Duke University · Sites in United States
Ages 1 mo+ · Healthy volunteers
Life Biosciences Inc. · Sites in United States
Ages 40–85
Washington University School of Medicine · Sites in United States
Ages 50+
MediBeacon · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 44 Retinal Diseases studies recruiting now, 30 (68%) set no upper age limit and 4 (9%) stop at 75 or younger; 16 take children under 18; 19 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
162 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 49 · Phase 3 21 · Phase 4 1
First in 1992; this study’s year is marked. 16 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 51 across 207 interventional studies indexed under Retinal Diseases.
Median enrollment 36 across the 111 interventional studies, 120 across the 51 observational. Of the 113 that completed or were terminated, 44 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
86 of 162 have an industry lead sponsor. The 10 most frequent:
Optos, PLC is the lead sponsor of 18 studies on the registry; 3 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
Optos, PLC has 7 studies filed under Retinal Diseases — fewer than ten, so there is no comparison to draw.
14 of the studies in Retinal Diseases with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04704921Phase 3AbbViePivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | 2026-12 |
| NCT05750589Phase 3iRenix Medical, Inc.Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections | 2027-01-31 |
| NCT06891443Phase 3Laboratoires TheaStudy to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) | 2027-11 |
| NCT06380075University of Wisconsin, MadisonCOmparison of Clarus and Optos Ultrawide Field Imaging Systems for Inherited Retinal Disease | 2026-12 |
| NCT04008121MediBeaconFeasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium | 2026-12 |
Add all 14 to your calendar (.ics) → With an account.
Among the 162 studies in Retinal Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study evaluates image quality between two devices.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: P200TxE · Device: P200DTx
The P200TxE ophthalmoscope provides widefield scanning laser ophthalmascope (SLO) fundus imaging.
The P200DTx ophthalmoscope provides widefield scanning laser ophthalmascope (SLO) fundus imaging.
Qualitative Image assessment
Results from a qualitative assessment of the clinical utility and image quality of the images from both devices will be assessed from a clinician questionnaire and three independent masked and qualified graders using a four point scale (0-3).
Time frame: 6 months
Safety Assessment from Adverse Events
Analysis of safety will be assessed through adverse events reported by the site and documented on each subject's case report form.
Time frame: 6 months
Ran from Jun 2019 to primary completion in Jan 2020, 6 months.
Of 42 interventional studies with no phase under Retinal Diseases, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 66. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Optos, PLC